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Abstract
Background: Non-adherence to r-hGH treatments occurs in a variable percentage of 
subjects. One problem found when evaluating adherence is the great variability in 
methods of detection and definitions utilized in studies. This study assessed the level of 
adherence in subjects receiving r-hGH with the easypod™ electronic device.
Methods: National, multicenter, prospective and observational study involving 238 
subjects (144 with GH deficiency (GHD), and 86 with small for gestational age (SGA), 8 
with Turner Syndrome), who received r-hGH with easypod™ for at least 3 months before 
inclusion. The follow-up period was 4 years.
Results: Overall adherence was 94.5%; 97.5% after 6 months, 95.3% after 1 year, 93.7% 
after 2, 94.4% after 3 and 95.5% after 4 years of treatment. No differences in adherence 
were observed between prepubertal and pubertal groups and GHD and SGA groups. 
Change in height after 1 and 2 years, change in height SDS after 1 and 2 years, HV after  
1 year, HV SDS after at 1 and 4 years, change in BMI after 1 year and change in BMI SDS 
at 1 and 2 years showed significant correlation with adherence. No significant differences 
in adherence according to IGF-I levels were found in follow-up visits or between groups.
Conclusions: The easypod™ electronic device, apart from being a precise and objective 
measure of adherence to r-hGH treatment, allows high compliance rates to be achieved 
over long periods of time. Adherence significantly impacts growth outcomes associated 
with r-hGH treatment.
Introduction
Since the 60s, GH has been the mainstay of treatment for 
children with GH deficiency (GHD) (1). With the discovery 
of recombinant human growth hormone (r-hGH), 
the treatment has been extended to other conditions, 
such as Turner syndrome (TS), chronic renal insufficiency 
(CRI) and children born small for gestational age (SGA) 
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(2, 3). Pathologies requiring the administration of 
r-hGH in pediatric patients show a great variability 
in severity (especially among secretion pathologies) 
and in sensitivity to the hormone (4). Treatment with 
r-hGH has been shown to be effective in children and 
adolescents with GHD, increasing short-term growth 
and adult height (5, 6). GH therapy requires daily 
subcutaneous injections for long periods of time (7). 
Some studies have suggested that non-adherence to 
treatment occurs in a variable percentage of subjects 
(8, 9, 10). The main cause for minor efficacy in r-hGH 
therapy is the lack of adherence to treatment or non-
persistence with the prescription (11). Since dosing has 
to be adjusted depending on the response to treatment, 
it is necessary, initially, to ensure adherence to treatment 
in order to evaluate its response. Non-adherence to the 
prescribed treatment is directly associated with worse 
clinical outcomes, increased healthcare costs and may 
affect the benefit–risk balance of treatments, especially 
in chronic diseases (12). One of the problems found at 
the time of evaluating adherence to r-hGH treatments 
is the great variability in methods of detection and 
definitions of adherence utilized in studies (8, 9, 
10). To provide a precise and objective measure of 
adherence, electronic devices can be used to monitor 
and administer treatment. The r-hGH electronic auto-
injector device, easypod™ (Merck Serono International 
S.A.), has been specifically designed to ease the use 
of these daily injectors and to provide reliability and 
convenience to users by recording the dosing history 
and using preprogrammed doses; in other words, to 
provide an e-health tool to patients (13). Despite this 
term has evolved in the last decade, e-health is defined 
by the World Health Organization (WHO) as ‘the use 
of information and communication technologies 
for health’ (14). Since easypod™ records the number 
of doses administered, adherence can be accurately 
assessed. The multinational easypod™ connect 
observational study (ECOS) was specifically designed 
to quantify adherence in subjects receiving r-hGH with 
easypod™ and to characterize the impact of adherence 
on clinical outcomes and identify adherence patterns 
(15). This study aimed to evaluate adherence as a factor 
involved in the response to treatments with r-hGH. 
The present manuscript shows results obtained from 
the Spanish ECOS study (ClinicalTrials.gov identifier: 
NCT01376921) and the main objective of the study was 
to assess the level of adherence in subjects receiving 
r-hGH with the electronic device, easypod™.
Subjects and methods
Patients
This national, multicenter, observational study involved 
subjects aged between 2 and 18 years old or over 18 
years with no fusion of growth plates, who received 
r-hGH (Saizen®, Merck Serono S.A.) with the easypod™ 
electronic device for at least 3 months before inclusion 
into the study. The period of follow-up was up to 5 years; 
however, due the low number of patients at that time, 
results are only shown for up to 4 years. Exclusion criteria 
to participate in the study were previous treatment with 
r-hGH other than Saizen®; hypersensitivity to the active 
ingredient or excipients; subjects with fused growth 
plates; contraindications to r-hGH or participating in 
another clinical study. Subjects were identified from the 
investigator’s review of medical charts. Informed consent 
signed by parents or legal guardians was obtained from 
all subjects. All procedures were in accordance with 
the Declaration of Helsinki and approved by the Ethics 
Committee of each participating center.
Endpoints and variables
The primary endpoint was the adherence to treatment 
over a follow-up period of 4 years. Adherence data were 
collected by the means of easypod™ and uploaded at every 
follow-up visit or at any time point adjacent to the visit 
if collected remotely, depending on the clinical practice. 
Adherence was calculated as the percentage of injections 
received (days) with respect to planned injections. The 
compliant population was defined as those with ≥85% 
adherence to prescribed treatment (no more than 1 
missed dose a week on average) (16). Secondary endpoints 
included evaluation of the impact of adherence on growth 
outcomes over the follow-up period; identification of 
demographic and auxological characteristics of subjects 
associated with adherence and assessment of the impact 
of insulin-like growth factor I (IGF-I) levels on adherence 
over the follow-up period. Demographic, auxological and 
diagnostic data were obtained from medical charts. All 
data were collected both retrospectively and prospectively. 
In contrast with the global ECOS study, demographics, 
historical information on growth hormone treatment, 
auxological parameters and adherence were transcribed 
by investigators onto paper case report forms and not 
reported electronically. Growth outcomes included 
height, height standard deviation score (SDS), change 
in height, change in height SDS, height velocity (HV), 
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HV SDS, change in HV, change in HV SDS, weight, weight 
SDS, change in weight, change in weight SDS, BMI, BMI 
SDS, change in BMI and change in BMI SDS. The SDS 
variables were calculated by adjusting data with age and 
gender, according to child growth standards (17). Bone age 
was measured using the Greulich and Pyle method (18). 
The IGF-I concentration was classified as high, normal or 
low according to standard laboratory ranges (established 
on the heterogeneity of techniques used in the present 
multicenter study). The proportion of subjects with dose 
changes was calculated as a percentage of the number of 
visits with dose changes over the total number of visits.
Determination of sample size and 
statistical analysis
The ECOS Spain study was planned to be implemented 
in 50 centers and expected to recruit 300 subjects. 
Treatment adherence data of 300 subjects would be able 
to compute the 95% confidence interval (95% CI) around 
the observed mean percent of adherence with a precision 
of ±1.7% assuming a standard deviation (s.d.) of 16%. 
Statistical analysis was performed on the full analysis set 
(FAS) subpopulation. The FAS subpopulation included 
subjects with GHD, SGA and TS, according to the new 
definition established by investigators on June 3, 2016. 
The FAS subpopulation was also stratified by prepubertal 
(Tanner stage 1) and pubertal subjects (Tanner stage 2–4). 
Due to low numbers, subjects with TS were excluded from 
analyses. Categorical variables were expressed as absolute 
and relative (%) frequencies; whereas continuous variables 
as the mean, median, s.d. and 95% CI. Parametric or non-
parametric analyses were carried out depending on results 
of the normality test of each variable. The impact of 
adherence on growth outcomes at the different follow-up 
visits was determined by non-parametric Spearman’s 
correlation analysis. The correlation between compliance 
and growth outcomes, and the impact of adherence on 
serum IGF-I levels was measured by using a t-test or the 
Wilcoxon–Mann–Whitney test. The identification of 
demographic and auxological characteristics associated 
with adherence was performed with a multiple linear 
regression model. The following predictor variables 
were considered: age (at inclusion and when starting 
r-hGH treatment with easypod™), gender, indication 
(GHD or SGA), person who performed the majority of 
injections, treatment duration, and height SDS before 
start of GH treatment. Those variables with a statistical 
significance (P > 0.1) were included in the model. 
All statistical procedures were performed using SAS version 
9.4. Statistical significance was established when P ≤ 0.05.
Results
Characteristics of subjects and treatment
A total of 272 subjects consented to participate in the 
study. Among them, 238 (87.5%) were included in the 
FAS subpopulation; 212 (89.1%) in the prepubertal and 
26 (10.9%) in the pubertal group. The main reason for 
discontinuation (80.6% of cases) was due to the closure 
of the study by the sponsor at which point subjects were 
followed up for at least one year. The FAS subpopulation 
included 235 (209 prepubertal and 26 pubertal) subjects 
at 6 months and 1 year after starting the treatment, 
176 (160 and 16, respectively) subjects at 2 years, 84 
(80 and 4, respectively) subjects at 3 years and 25 (24 
and 1, respectively) subjects at 4 years. In the FAS 
subpopulation, there were no data from three patients 
regarding if prepubertal or pubertal. In total, 144 subjects 
presented with GHD, 86 with SGA and 8 with TS. 
Baseline sociodemographic and clinical characteristics 
of patients are shown in Table 1. Subjects had a mean 
age at inclusion of 9.0 ± 3.3 years; approximately half 
of them were male (51.7%), mainly Caucasian (94.1%). 
At the time of starting treatment with easypod™, 
mean height SDS and velocity SDS were −2.6 ± 0.8 and 
−2.0 ± 1.7, respectively. No differences in demographic 
and auxological variables in terms of SDS values were 
observed between prepubertal (n = 212) and pubertal 
(n = 26) groups. At baseline, 73.1, 23.1 and 3.8% of pubertal 
subjects had Tanner Stage 2, 3 or 4, respectively. Mean 
bone age for the prepubertal GHD population (n = 119) 
was 6.0 ± 3.1 years, whereas their mean chronological age 
at inclusion was 9.2 ± 3.1 years. The mean duration of 
treatment was 26.6 ± 11.6 months (27.2 ± 11.7 months in 
the prepubertal group, 22.0 ± 8.9 months in the pubertal 
group, 27.4 ± 11.9 months in the GHD population, and 
25.5 ± 10.7 months in the SGA population). Changes 
in prescribed dose were documented in 61.7 ± 20.2% of 
visits over the treatment period; for adjusting it to the 
recommending dose (mg/kg/day). The main reasons 
for missed injections were forgetting to inject (78.0%), 
and holidays, long weekends or not sleeping at home 
(51.8%). No significant differences were found regarding 
missed injections and the person who performed the 
majority of injections.
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Adherence rates
Mean overall adherence to the treatment was 94.5% 
(95% CI 92.7–96.3%; Table 2). Adherence was higher 
than 90% in all follow-up visits, that is 97.5% 
(95% CI 96.5–98.5%, n = 234) after 6 months, 95.3% 
(95% CI 93.3–97.2%, n = 232) after 1 year, 93.7% 
(95% CI 91.1–96.2%, n = 174) after 2 years, 94.4% (95% CI 
91.5–97.3%, n = 84) after 3 years and 95.5% (95% CI 
92.7–98.3%, n = 25) after 4 years of starting treatment 
with easypod™. Adherence for prepubertal and pubertal 
groups was 94.4% (95% CI 92.4–96.4%) and 95.5% 
(95% CI 92.8–98.1%), respectively. In the case of the 
GHD and SGA populations, adherence was 95.2% 
(95% CI 93.3–97.0%) and 93.0% (95% CI 89.1–96.9%). 
No differences in adherence were observed between 
the prepubertal and pubertal groups or the GHD and 
SGA populations. Adherence to treatment among the 
compliant population (≥85% adherence) was 97.5% 
after 6 months, 93.2% after 1 year, 92.1% after 2 years, 
91.7% after 3 years and 92.0% after 4 years of starting 
treatment with easypod™ (Fig. 1).
Table 1 Characteristics of subjects and treatment with easypod™.
Total (n = 238) Prepubertal (n = 212) Pubertal (n = 26) GHD (n = 144) SGA (n = 86)
Age
 At inclusion, mean years ± s.d. 9.0 ± 3.3 8.5 ± 3.1 13.4 ± 3.1 9.9 ± 3.4 7.7 ± 2.7
 At start of treatment with easypod™, 
mean years ± s.d.
7.9 ± 3.2 7.3 ± 2.9 12.5 ± 1.8 8.7 ± 3.3 6.6 ± 2.5
Gender, n (%)
 Male 123 (51.7) 112 (52.8) 11 (42.3) 78 (54.2) 45 (52.3)
 Female 115 (48.3) 100 (47.2) 15 (57.7) 66 (45.8) 41 (47.7)
Ethnicity, n (%)
 Caucasian 224 (94.1) 199 (93.9) 25 (96.2) 135 (93.8) 81 (94.2)
 African 1 (0.4) 1 (0.5) 0 (0.0) 1 (0.7) 0 (0.0)
 Asian 3 (1.3) 3 (1.4) 0 (0.0) 2 (1.4) 1 (1.2)
 Other 10 (4.2) 9 (4.8) 1 (3.8) 6 (4.2) 4 (4.7)
Auxological data before starting treatment
 Height SDS, mean (s.d.) −2.6 (0.8) −2.6 (0.7) −2.2 (1.1) −2.5 (0.8) −2.6 (0.6)
 Weight SDS, mean (s.d.) −1.3 (0.9) −1.3 (0.9) 0.9 −1.1 (1.0) −1.5 (0.8)
 HV SDS, mean (s.d.) −2.0 (1.7) −2.0 (1.6) −2.3 (2.3) −2.4 (1.7) −1.5 (1.5)
 BMI SDS 0.2 (1.4) 0.2 (1.4) 0.3 (1.3) 0.3 (1.5) −0.2 (1.1)
 Bone age, years (s.d.) 6.0 (3.3) 5.4 (2.9) 11.0 (1.3) 6.7 (3.4) 4.8 (2.7)
Treatment with r-hGH
 Prescribed dose, mean mg/kg/day (s.d.) 0.032 (0.005) 0.032 (0.005) 0.033 (0.006) 0.030 (0.004) 0.035 (0.004)
 Percentage of reported changes in the 
prescribed doses over the treatment 
period, mean % ± s.d.
61.7 ± 20.2 62.0 ± 20.5 58.8 ± 18.1 59.1 ± 22.4 66.1 ± 15.6
 Duration of treatment period, mean 
months (s.d.)
26.6 (11.6) 27.2 (11.7) 22.0 (8.9) 27.4 (11.9) 25.5 (10.7)
Person who performed majority of injections, n (%)
 Parents/legal guardian 161 (67.6) 154 (72.6) 7 (26.9) 85 (59.0) 70 (81.4)
 Under parent supervision 54 (22.7) 42 (19.8) 12 (46.2) 40 (27.8) 12 (14.0)
 Self-injections 17 (7.1) 11 (5.2) 6 (23.1) 14 (9.7) 3 (3.5)
 Not available 6 (2.5) 5 (2.4) 1 (3.8) 5 (3.5) 1 (1.2)
Missed some injection over the treatment 
period, n (%)
195 (81.9) 173 (81.6) 22 (84.6) 115 (79.9) 73 (84.9)
 Reasons for missing injections, n (%)
  Forgot injection 152 (78.0) 137 (79.2) 15 (68.2) 90 (78.3) 55 (75.3)
  Holidays/long weekend/not sleeping 
at home
101 (51.8) 90 (52.0) 11 (50.0) 57 (49.6) 42 (57.5)
  Medical reasons 6 (3.1) 5 (2.9) 1 (4.6) 4 (3.5) 2 (2.7)
  Tired of injections 7 (3.6) 5 (2.9) 2 (9.1) 4 (3.5) 3 (4.1)
  Technical problems with easypod™ 14 (7.2) 11 (6.4) 3 (13.6) 6 (5.2) 8 (11.0)
  Forgot drug/Easypod™ 15 (7.7) 12 (6.9) 3 (13.6) 10 (8.7) 5 (6.9)
  Ran out of needle/cartridge 7 (3.6) 7 (4.1) 0 (0.0) 3 (2.6) 4 (5.5)
  Others 20 (10.3) 18 (10.4) 2 (9.1) 11 (9.6) 7 (9.6)
BMI, body mass index; GHD, growth hormone deficiency; HV, height velocity; s.d., standard deviation; SDS, standard deviation score; SGA, small for 
gestational age.
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IGF-I levels and adherence
The IGF-I values were below the laboratory range at 
baseline in 29.0% of subjects. Among these subjects, 
76.6% showed IGF-I values within/above laboratory range 
after 6 months, 91.7% after 1 year, 93.0% at 2 years, 100% 
after 3 years and 75.0% after 4 years of starting treatment 
(Table 3). No significant differences in adherence rate 
according to IGF-I levels were found in any of the 
follow-up visits or between prepubertal and pubertal 
groups or GHD and SGA populations.
Impact of adherence on growth outcomes
Overall change in height after 1 and 2 years (Spearman’s 
correlation = 0.170 and 0.217; P = 0.010 and 0.04, 
respectively), change in height SDS after 1 and 2 years 
(correlation = 0.161 and 0.160; P = 0.015 and 0.035, 
respectively), HV after 1 year (correlation = 0.206; 
P = 0.002), HV SDS after at 1 and 4 years (correlation = 0.168 
and −0.473; P = 0.011 and 0.041, respectively), change 
in BMI after 1 year (correlation = −0.193; P = 0.003) and 
change in BMI SDS at 1 and 2 years (correlation = −0.238 
and −0.171; P = 0.002 and 0.051) showed significant 
correlation with adherence (Table 4). Regarding the 
GHD population, change in height after 2 years 
(Spearman’s correlation = 0.203; P = 0.037), height SDS 
after 1 year (correlation = 0.169; P = 0.046), HV after 1 
year (correlation = 0.224; P = 0.008), change in BMI after 
2 years (correlation = −0.193; P = 0.047) and change in 
BMI SDS after 2 years (correlation = −0.214; P = 0.047) 
showed a significant correlation with adherence. In the 
case of the SGA population, only change in BMI after 
1 year (correlation = −0.246; P = 0.025) and change in 
BMI SDS after 1 year (correlation = −0.2350; P = 0.016) 
showed a significant correlation with adherence. The 
remaining growth outcomes showed no differences 
between the compliant and non-compliant populations. 
In the compliant GHD population, the following 
outcomes were higher than in non-compliant GHD 
population: height SDS after 2 years (−1.5 ± 0.8 vs 
−2.0 ± 0.6, P = 0.047), HV after 2 years (7.6 ± 1.6 cm/year 
vs 6.0 ± 1.5 cm/year, P = 0.013), weight after 3 years 
(35.8 ± 13.1 kg vs 24.5 ± 10.8 kg, P = 0.025) and change in 
weight after 3 years (13.0 ± 5.7 kg vs 8.4 ± 2.1 kg, P = 0.048). 
In the SGA population, change in weight after 2 years 
was significantly higher in the compliant subpopulation 
(7.1 ± 3.0 kg) than the non-compliant subpopulation 
(4.5 ± 0.3 kg, P = 0.017).Ta
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Figure 1
Percentage of compliant population through 4 years of treatment. Blue boxes represent the limits between the 25 and 75% confidence interval. Median 
and mean values are shown as white lines and red squares, respectively.
Table 3 Baseline IGF-I and percentage of adherence regarding IGF-I levels after starting treatment with easypod™ (IGF-I levels 
were not associated with percentage of adherence).
IGF-I laboratory 
range
Number of patients regarding IGF-I (%)
Total Prepubertal Pubertal GHD SGA
Baseline 
IGF-I
Above 3 (1.3) 2 (0.9) 1 (3.9) 1 (0.7) 1 (1.2)
Within 144 (60.5) 127 (59.9) 17 (65.4) 75 (52.1) 62 (72.1)
Below 69 (29.0) 64 (30.2) 5 (19.2) 55 (38.2) 14 (16.3)
  Adherence, mean % (s.d.)
Total Prepubertal Pubertal GHD SGA
After 6 
months
Above 98.2 ± 2.3 98.6 ± 2.2 96.6 ± 2.1 97.7 ± 2.4 100.0
Within 97.0 ± 10.0 97.4 ± 10.1 93.6 ± 9.3 96.2 ± 13.0 98.0 ± 2.9
Below 98.3 ± 2.6 98.0 ± 2.7 100.0 98.0 ± 2.7 100.0
After 1 year Above 97.6 ± 4.4 97.6 ± 4.8 97.7 ± 2.3 97.5 ± 5.2 97.7 ± 3.2
Within 96.5 ± 11.9 96.3 ± 12.5 97.9 ± 2.6 95.8 ± 14.6 97.3 ± 6.4
Below 92.2 ± 15.4 92.2 ± 15.4 N.A. 92.2 ± 15.4 N.A.
After 2 
years
Above 91.0 ± 24.1 90.9 ± 25.3 91.4 ± 15.7 91.4 ± 24.4 89.2 ± 26.5
Within 95.4 ± 11.4 95.3 ± 11.9 96.4 ± 3.4 95.0 ± 13.6 95.9 ± 6.8
Below 87.1 ± 12.1 87.1 ± 12.1 N.A. 87.1 ± 12.1 N.A.
After 3 
years
Above 98.2 ± 1.9 98.2 ± 1.9 N.A. 98.2 ± 2.4 98.3 ± 1.6
Within 93.6 ± 15.7 93.4 ± 16.1 96.8 ± 2.0 95.7 ± 9.3 87.9 ± 25.7
Below N.A. N.A. N.A. N.A. N.A.
After 4 
years
Above 96.0 ± 3.5 96.0 ± 3.5 N.A. 96.0 ± 3.5 96.2 ± 5.1
Within 98.2 ± 1.6 98.2 ± 1.6 N.A. 99.2 ± 0.7 97.9 ± 1.8
Below 96.4 96.4 N.A. 96.4 N.A.
GHD, growth hormone deficiency; IGF-I, insulin-like growth factor I; N.A., not available (n = 0); s.d., standard deviation; SGA, small for gestational age.
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Subject’s characteristics associated with adherence
In the univariate analysis, age at inclusion and at start 
of treatment, duration of treatment and height SDS 
before starting treatment showed a P value of 0.10 and 
were therefore included in the multivariate analysis. This 
multiple linear regression model did not show significant 
differences on treatment adherence (data not shown). In 
the GHD population, female subjects (96.4%) showed a 
significant higher adherence than male subjects (94.2%, 
P = 0.037). Results of the multiple linear regression 
model in the GHD and SGA populations did not show 
significant differences on treatment adherence when 
adjusted for other factors such as age at inclusion and 
at start of treatment, duration of treatment and height 
SDS in the FAS subpopulation or the prepubertal and 
pubertal groups.
Discussion
Non-adherence is an important problem in chronic 
pathologies for national healthcare systems as it interferes 
with the effectiveness of treatments, leading to poor 
clinical outcomes and increased healthcare costs (10, 
19, 20). A parent or guardian is required to perform the 
injections for pediatrics, and children and adolescents are 
usually reticent to receive them (19). Treatment devices 
are frequently used to address this issue, especially by 
favoring self-injection (such as the electronic ones). 
The prevalence of non-adherence has been reported to 
range from 5 to 82% (9), with overall values between 
36 and 49% (8). A Spanish study involving 158 children 
(121 with GHD and 37 with SGA) receiving r-hGH showed 
that 33.5% presented a moderate-to-poor adherence 
(defined by authors as <92% adherence) (10). Adherence, 
measured according to issued r-hGH prescriptions, was 
indeed significantly correlated with HV and IGF-I levels. 
Despite these results, only electronic devices can provide 
a precise and objective measure of adherence (13, 15). 
To our knowledge, there are scarce studies specifically 
designed to measure adherence by using the electronic 
device, easypod™ (21, 22, 23, 24, 25, 26). Recently, the 
ECOS study (global, i.e. using overall data of 1190 children 
from 24 national ECOS studies) has evidenced a median 
overall rate of adherence of 93.7% (26). An international, 
multicenter, observational study that evaluated 824 
children who received r-hGH as part of their normal 
care for 3 months, reported a rate of adherence (>92% 
of injections prescribed) of 87.5% using easypod™ (21). 
Interestingly, children also completed a questionnaire-
based survey to measure adherence and the adherence 
rate was shown to be 90.2%. A retrospective multicenter 
study from Spain with 504 r-hGH-naïve children with 
growth disorders receiving r-hGH with easypod™ (in 
81.5% of cases) showed that only 7.4% of children were 
not completely adherent (24). Adherence rates from 
our study (overall 94.5%) were as high as described in 
literature using easypod™, and maintained over 4 years 
of follow-up; however, rates were higher than previously 
reported in questionnaire-based retrospective studies (9, 
16, 21). Furthermore, adherence rates were higher than 
those in studies using auto-injector devices in diseases such 
as diabetes and multiple sclerosis (ranging between 60 and 
88%) (27, 28, 29). Studies using needle-free auto-injectors 
with r-hGH in children (such as Zoma-Jet) have reported 
Table 4 Significant impact of adherence on growth outcomes at different follow-up visits, groups and populations.
Spearman’s correlation (P value)
Total Prepubertal Pubertal GHD SGA
Change in height after 1 year 0.170 (0.010)a 0.162 (0.021)a 0.250 (0.229) 0.147 (0.084) 0.176 (0.111)
 2 years 0.217 (0.004)a 0.216 (0.007)a 0.281 (0.292) 0.203 (0.037)a 0.242 (0.056)
Change in height SDS after 1 year 0.161 (0.015)a 0.157 (0.025)a 0.171 (0.414) 0.144 (0.089) 0.173 (0.117)
 2 years 0.160 (0.035)a 0.119 (0.137) 0.611 (0.012)a 0.146 (0.136) 0.227 (0.073)
Height SDS after 1 year 0.092 (0.164) 0.092 (0.189) 0.144 (0.493) 0.169 (0.046)a −0.075 (0.499)
HV after 1 year 0.206 (0.002)a 0.186 (0.008)a 0.349 (0.084) 0.224 (0.008)a 0.114 (0.304)
HV SDS after 1 year 0.168 (0.011)a 0.193 (0.006)a −0.065 (0.759) 0.154 (0.070) 0.152 (0.171)
 4 years −0.473 (0.041)a −0.473 (0.041)a N.A. −0.283 (0.348) −0.943 (0.005)a
Change in BMI after 1 year −0.193 (0.003)a −0.162 (0.020)a −0.364 (0.074) −0.150 (0.077) −0.246 (0.025)a
 2 years −0.126 (0.099) −0.069 (0.389) −0.609 (0.012)a −0.193 (0.047)a −0.064 (0.619)
Change in BMI SDS after 1 year −0.238 (0.002)a −0.214 (0.011)a −0.327 (0.111) −0.181 (0.055) −0.350 (0.016)a
 2 years −0.171 (0.051)a −0.137 (0.146) −0.636 (0.008)a −0.214 (0.047)a −0.214 (0.185)
aSignificant correlation.
BMI, body mass index; GHD, growth hormone deficiency; HV, height velocity; N.A., not available (n = 0); SDS, standard deviation score; SGA, small for 
gestational age.
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adherence rates from 58% (30) to 97% (31). In our study, 
no significant differences in adherence to treatment were 
found between the prepubertal and pubertal groups or the 
GHD (95.2%) and SGA (93.0%) populations. This result is 
in concordance with ECOS study (global), which showed 
median adherences of 93.4 and 95.0%, respectively (26). 
The use of easypod™ might induce Hawthorne effect 
on patients. It would also be interesting to evaluate 
the Hawthorne effect in patients receiving r-hGH with 
easypod™. The Hawthorne effect refers to the change in 
the behavior of some individuals participating in clinical 
trials, feeling that they are being monitored and resulting 
in better adherence rates and results (32). According to 
some authors (33), levels of IGF-I are not good indicators 
for adherence because influenced by factors (such as 
weight, etiology of GHD or nutrition). This statement is 
supported by no correlation between levels of IGF-I and 
adherence found in our study. Furthermore, IGF-I levels 
only would demonstrate adherence of the treatment just 
one the previous week to the analysis (34).
On the other hand, in our study, change in height 
and height SDS, HV and HV SDS showed significant, 
although weak, correlations with adherence. These 
results are in concordance with literature and highlight 
the importance of adherence on clinical outcomes of the 
treatment (16, 21). In ECOS study (global), adherence 
showed a significant positive correlation with change 
in height, change in height SDS, HV and HV SDS; all 
of them after 1 year (26). It is interesting to note that 
change, in our study, height SDS after 3 years of treatment 
was higher in patients with >85% adherence. Given the 
weak correlations between adherence rate and growth 
parameters found in our study, conclusions (clinical 
implications) should be carefully considered.
Finally, some patient factors, such as age and gender, 
have been shown to influence the response to GH therapies 
(35). In our study, we failed to identify demographic and 
auxological characteristics in subjects associated with 
adherence and growth outcomes over 4-year follow-up. 
Nevertheless, our predictive variables, including age 
at inclusion, age when starting r-hGH treatment with 
easypod™, gender, indication, person who performed 
injections, treatment duration and height SDS before start 
of GH treatment, were consistent with those selected in 
prediction models for long-term growth responses (36). 
Besides this, in the GHD population, female subjects 
showed a higher adherence rate than males.
One limitation of the present study was its 
observational nature as it was not specifically designed 
(primary objective) to determine the impact of adherence 
to the treatment on clinical outcomes. The number 
of patients with low adherence rates (non-compliant 
population) was very low, which made it impossible to 
implement such an analysis. Another limitation was 
the lack of a control group for comparison purposes. A 
control group would improve the methodological design 
of the study and would inform whether or not easypod™ 
increases the adherence or increases the possibility to 
monitor the adherence. Nevertheless, in our opinion, 
comparing our results with data from other published 
studies was also a pertinent option. Moreover, our results 
are in concordance with literature, such as ECOS study 
(global) (26). Further studies, specifically designed to 
evaluate clinical implications of adherence to r-hGH that 
involve long periods of time (for example, beyond the 
fourth year of treatment to evaluate long-term adherence) 
are thus required. The goal of the present study was to 
evaluate prospectively the adherence to r-hGH treatment, 
accurately with easypod™, and identify the associations 
with growth outcomes and biomarkers, such as IGF-I, for 
an extended period of time.
Conclusions
Subjects receiving r-hGH with the electronic device 
easypod™ showed and maintained high adherence 
to the treatment through 4 years of follow-up, in both 
prepubertal and pubertal subjects, and in both GHD and 
SGA populations. Adherence significantly impacts growth 
outcomes of r-hGH treatment. Knowing accurately the 
adherence to treatment allows clinicians to establish the 
best approach and adequate dose-adjustment for patients 
with GHD. Electronic devices, such as easypod™, are the 
only tools to determine with precision the adherence 
to treatments with r-hGH. Moreover, they provide this 
information without the patient being physically present 
during the consultation. This emerging field of e-health 
allows activities to be performed that are aimed to improve 
adherence to treatments (such as supporting nursing 
programs or motivational messaging), through the use of 
digital health tools, the Internet and related technologies.
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